The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells

PARP inhibitor (PARPi) is widely used to treat BRCA1/2-deficient tumors, but why PARPi is more effective than other DNA-damaging drugs is unclear. Here, we show that PARPi generates DNA double-strand breaks (DSBs) predominantly in a trans cell cycle manner. During the first S phase after PARPi expos...

Descripción completa

Detalles Bibliográficos
Autores principales: Simoneau, Antoine, Xiong, Rosalinda, Zou, Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415318/
https://www.ncbi.nlm.nih.gov/pubmed/34385259
http://dx.doi.org/10.1101/gad.348479.121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415318/
https://www.ncbi.nlm.nih.gov/pubmed/34385259
http://dx.doi.org/10.1101/gad.348479.121

Ejemplares similares